Compare Sanofi SA (SNY) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Invesco S&P 500 Low Volatility ETF — how do they compare? Sanofi SA trades at $40.1 (market cap $96.81B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $7.00B). The key difference: Sanofi SA is far larger — about 13.8× Invesco S&P 500 Low Volatility ETF's market cap, and Sanofi SA pays a 6.02% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| SNY | SPLV | |
|---|---|---|
Market Cap | $96.81B | $7.00B |
Volume | 2,081,815 | 1,622,563 |
Sector | Health | — |
52-Week High | $52.34 | $77.97 |
52-Week Low | $39.51 | $70.30 |
Typical Hold Time | 94 Days | 123 Days |
Enterprise Value | $116.20B | — |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
SPLV trades at $71.22, down 0.71% with a bearish technical signal from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 per share were distributed in July and September 2026, while technical indicators show mixed signals with neutral RSI readings but strong bearish ADX momentum.
The outlook remains challenged by sector headwinds and unappealing growth-adjusted valuation at 19.5x P/E. Key risks include continued underperformance relative to broader market and sensitivity to interest rate movements. Opportunities exist for investors seeking low-volatility exposure during market uncertainty, though near-term catalysts appear limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
